CalciMedica, Inc. (NasdaqCM: CALC)
Health Care · Pharmaceuticals · US
$0.56
-17.58% today · -77.1% 1Y
CalciMedica, Inc. (NasdaqCM: CALC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $23.05M and employs 16 people.
Over the last twelve months the share price has lost 77.1%, trading between 0.46 and 7.20.
Tweenvest scores CalciMedica, Inc. across four factors: quality 25/100. Its strongest factor is quality.
CALC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.05M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.33
- Dividend yield
- —
- Beta (5Y)
- 1.20
- 52-week high
- $7.20
- 52-week low
- $0.46
- Avg volume (3M)
- —
- Shares outstanding
- 34.14M
- Employees
- 16
- Next earnings
- —
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
- ISIN
- US38942Q2021
- Listed since
- Jun 14, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,248.37 | +0.12% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.28 | -0.64% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.36 | +0.46% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.80 | +0.11% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.72 | +0.51% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.